经皮穴位电刺激对比地塞米松预防乳腺手术后恶心呕吐的非劣效随机对照试验
该非劣效随机对照试验纳入280例乳腺手术女性患者,比较内关穴(PC6)经皮穴位电刺激与地塞米松预防术后恶心呕吐的效果。结果显示术后0至24小时经皮穴位电刺激组恶心呕吐发生率不劣于地塞米松组,且患者满意度评分更高,PC6患者自控经皮穴位电刺激方案可行。
要点
- 术后0至24小时经皮穴位电刺激预防恶心呕吐不劣于地塞米松
- 经皮穴位电刺激组患者满意度评分高于地塞米松组
- PC6患者自控经皮穴位电刺激预防方案具有可行性
核心结论
- 经皮穴位电刺激在乳腺手术后24小时内预防恶心呕吐不劣于地塞米松。
- 内关穴患者自控经皮穴位电刺激用于预防术后恶心呕吐是可行的。
研究设计与样本
- 非劣效随机对照试验,共280例女性乳腺手术患者。
- 随机分为经皮穴位电刺激组(n=140)和地塞米松组(n=140)。
主要发现
- 术后0至24小时恶心呕吐发生率:经皮穴位电刺激组31.1%,地塞米松组27.9%,符合方案风险差3.2(95%CI -7.7至14.0)。
- 意向性分析结果与符合方案分析一致:30.7% vs 27.1%,风险差3.6(95%CI -7.0至14.2)。
- 患者满意度评分经皮穴位电刺激组高于地塞米松组(3.9±0.1 vs 3.6±0.1,P=.003)。
关键数值与推荐
- 经皮穴位电刺激于麻醉诱导前0.5小时、进入麻醉后监护室即刻及离开后每3小时实施。
- 地塞米松组于麻醉诱导前0.5小时静脉给予地塞米松8 mg。
- 术后24小时记录恶心、呕吐、补救止吐药需求、满意度评分及PC6自控经皮穴位电刺激可行性。
临床怎么用
- 乳腺手术女性患者可考虑用PC6经皮穴位电刺激替代地塞米松预防术后恶心呕吐。
- 可指导患者家属协助实施PC6患者自控经皮穴位电刺激。
局限性
- 原文摘要未报告盲法、分配隐藏及随访时间等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcutaneous electrical acupoint stimulation and dexamethasone can reduce postoperative nausea and/or vomiting. In this noninferiority study, we compared the effects of Neiguan acupoint (PC6) transcutaneous electrical acupoint stimulation with dexamethasone to prevent postoperative nausea and/or vomiting in female patients undergoing breast surgery. METHODS: In total, 280 patients were randomized into the following 2 groups: transcutaneous electrical acupoint stimulation (n = 140) and dexamethasone (n = 140). Transcutaneous electrical acupoint stimulation was performed 0.5 hours before anesthesia induction, immediately after entering the post-anesthesia care unit, and every 3 hours after leaving the post-anesthesia care unit. In the postoperative ward, the anesthetist instructed the patient's family members to assist the patient with PC6 patient-controlled transcutaneous electrical acupoint stimulation. Patients in the dexamethasone group were given 8 mg dexamethasone (intravenously) at 0.5 hours before induction of anesthesia. The incidence of nausea, vomiting, need for rescue antiemetics, patient satisfaction score, and the feasibility results of PC6 patient-controlled transcutaneous electrical acupoint stimulation were recorded 24 hours after surgery. RESULT: Within 0 to 24 hours after surgery, the incidence of postoperative nausea and/or vomiting in the transcutaneous electrical acupoint stimulation group was not inferior to the dexamethasone group (31.1% vs 27.9%, per protocol risk difference 3.2; 95% confidence interval -7.7 to 14.0). The results of the intention-to-treat analysis (30.7% vs 27.1%, risk difference 3.6; 95% confidence interval -7.0 to 14.2) agreed with the per protocol analysis. Patient satisfaction score in the transcutaneous electrical acupoint stimulation group was higher than that in the dexamethasone group (3.9 ± 0.1 vs 3.6 ± 0.1, P = .003). The scheme of preventing postoperative nausea and/or vomiting by PC6 patient-controlled transcutaneous electrical acupoint stimulation was feasible. CONCLUSION: Transcutaneous electrical acupoint stimulation was noninferior to dexamethasone in preventing postoperative nausea and/or vomiting within 24 hours after breast surgery. Neiguan acupoint patient-controlled transcutaneous electrical acupoint stimulation was feasible to prevent postoperative nausea and/or vomiting.
引用
- Zhang Y, Li Y, Ji F, et al. Transcutaneous electrical acupoint stimulation versus dexamethasone for prophylaxis of postoperative nausea and vomiting in breast surgery: A non-inferiority randomized controlled trial. Surgery. 2023. PMID: 37482441. doi:10.1016/j.surg.2023.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。